Evoke Pharma Inc. (EVOK)
2.99
0.19 (6.63%)
At close: Mar 21, 2025, 3:58 PM
3.10
3.82%
After-hours: Mar 21, 2025, 06:48 PM EDT
6.63% (1D)
| Bid | 2.5 |
| Market Cap | 4.44M |
| Revenue (ttm) | 10.88M |
| Net Income (ttm) | -5.68M |
| EPS (ttm) | -2.81 |
| PE Ratio (ttm) | -1.06 |
| Forward PE | 9.27 |
| Analyst | n/a |
| Ask | 3.4 |
| Volume | 92,051 |
| Avg. Volume (20D) | 15,494 |
| Open | 2.81 |
| Previous Close | 2.80 |
| Day's Range | 2.50 - 3.13 |
| 52-Week Range | 2.50 - 12.32 |
| Beta | 0.12 |
About EVOK
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine ...
Sector Healthcare
IPO Date Sep 25, 2013
Employees 3
Stock Exchange NASDAQ
Ticker Symbol EVOK
Website https://www.evokepharma.com
Earnings Surprise
Evoke Pharma has released their quartely earnings
on Mar 13, 2025:
3 months ago
+24.77%
Evoke Pharma shares are trading higher after the c...
Unlock content with
Pro Subscription
4 months ago
+33.58%
Evoke Pharma shares are trading higher after the company announced the presentation of GLP-1 data for users with diabetic gastoparesis using GIMOTI and showed statistically significant improvements.
2 months ago · proactiveinvestors.co.uk
William Hill owner Evoke expects earnings to beat market forecastsExpect shares in William Hill owner Evoke PLC to get off to a strong start when the market opens. That's because the bookmaker said full-year earnings for 2024 will surpass market expectations, with s...